Companies House 15654391 2026-04-30 2026-04-30 2025-05-01 false iso4217:GBP xbrli:pure 15654391 2024-04-17 2025-04-30 15654391 2026-04-30 15654391 2025-05-01 2026-04-30 15654391 2025-04-30 15654391 curr:PoundSterling 2025-05-01 2026-04-30 15654391 uk-bus:CompanyLimitedByGuarantee 2025-05-01 2026-04-30 15654391 uk-bus:FRS102 2025-05-01 2026-04-30 15654391 uk-bus:AuditExempt-NoAccountantsReport 2025-05-01 2026-04-30 15654391 uk-bus:FullAccounts 2025-05-01 2026-04-30 15654391 uk-bus:RegisteredOffice 2025-05-01 2026-04-30 15654391 uk-bus:Director1 2025-05-01 2026-04-30 15654391 uk-bus:Director2 2025-05-01 2026-04-30 15654391 uk-bus:Director3 2025-05-01 2026-04-30 15654391 uk-bus:Director4 2025-05-01 2026-04-30 15654391 uk-bus:Director5 2025-05-01 2026-04-30 15654391 uk-bus:Director6 2025-05-01 2026-04-30 15654391 uk-bus:Director7 2025-05-01 2026-04-30 15654391 uk-bus:Director8 2025-05-01 2026-04-30 15654391 uk-bus:Director9 2025-05-01 2026-04-30 15654391 uk-bus:Director10 2025-05-01 2026-04-30 15654391 uk-bus:Director11 2025-05-01 2026-04-30 15654391 uk-bus:Director12 2025-05-01 2026-04-30 15654391 uk-bus:Director13 2025-05-01 2026-04-30 15654391 uk-bus:Director14 2025-05-01 2026-04-30 15654391 uk-bus:Director15 2025-05-01 2026-04-30 15654391 uk-bus:Director16 2025-05-01 2026-04-30 15654391 uk-bus:Director17 2025-05-01 2026-04-30 15654391 uk-bus:Director18 2025-05-01 2026-04-30 15654391 uk-bus:Director19 2025-05-01 2026-04-30 15654391 uk-bus:Director20 2025-05-01 2026-04-30 15654391 uk-bus:Director21 2025-05-01 2026-04-30 15654391 uk-bus:CompanySecretary1 2025-05-01 2026-04-30 15654391 core:AfterOneYear 2026-04-30 15654391 core:AfterOneYear 2025-04-30 15654391 core:WithinOneYear 2026-04-30 15654391 core:WithinOneYear 2025-04-30 15654391 core:WithinOneYear 2025-05-01 2026-04-30 15654391 core:AfterOneYear 2026-04-30 15654391 core:AfterOneYear 2025-04-30 15654391 core:AfterOneYear 2025-05-01 2026-04-30 15654391 core:ShareCapital 2026-04-30 15654391 core:ShareCapital 2025-04-30 15654391 core:SharePremium 2026-04-30 15654391 core:SharePremium 2025-04-30 15654391 core:OtherReservesSubtotal 2026-04-30 15654391 core:OtherReservesSubtotal 2025-04-30 15654391 core:RevaluationReserve 2026-04-30 15654391 core:RevaluationReserve 2025-04-30 15654391 core:RetainedEarningsAccumulatedLosses 2026-04-30 15654391 core:RetainedEarningsAccumulatedLosses 2025-04-30 15654391 1 2025-05-01 2026-04-30 15654391 2 2025-05-01 2026-04-30 15654391 3 2025-05-01 2026-04-30 15654391 core:LandBuildings 2025-05-01 2026-04-30 15654391 core:LandBuildings 2026-04-30 15654391 core:LandBuildings 2024-04-17 2025-04-30 15654391 core:LandBuildings 2025-04-30 15654391 core:PlantMachinery 2025-05-01 2026-04-30 15654391 core:PlantMachinery 2026-04-30 15654391 core:PlantMachinery 2024-04-17 2025-04-30 15654391 core:PlantMachinery 2025-04-30 15654391 core:FurnitureFittingsToolsEquipment 2025-05-01 2026-04-30 15654391 core:FurnitureFittingsToolsEquipment 2026-04-30 15654391 core:FurnitureFittingsToolsEquipment 2024-04-17 2025-04-30 15654391 core:FurnitureFittingsToolsEquipment 2025-04-30 15654391 core:OfficeEquipment 2025-05-01 2026-04-30 15654391 core:OfficeEquipment 2026-04-30 15654391 core:OfficeEquipment 2024-04-17 2025-04-30 15654391 core:OfficeEquipment 2025-04-30 15654391 core:Vehicles 2025-05-01 2026-04-30 15654391 core:Vehicles 2026-04-30 15654391 core:Vehicles 2024-04-17 2025-04-30 15654391 core:Vehicles 2025-04-30 15654391 core:NetGoodwill 2025-05-01 2026-04-30 15654391 core:NetGoodwill 2026-04-30 15654391 core:NetGoodwill 2024-04-17 2025-04-30 15654391 core:NetGoodwill 2025-04-30 15654391 core:IntangibleAssetsOtherThanGoodwill 2025-05-01 2026-04-30 15654391 core:IntangibleAssetsOtherThanGoodwill 2026-04-30 15654391 core:IntangibleAssetsOtherThanGoodwill 2024-04-17 2025-04-30 15654391 core:IntangibleAssetsOtherThanGoodwill 2025-04-30 15654391 uk-bus:Director2 1 2025-05-01 2026-04-30 15654391 uk-bus:Director2 1 2025-04-30 15654391 uk-bus:Director2 1 2026-04-30 15654391 uk-bus:Director2 2 2025-05-01 2026-04-30 15654391 uk-bus:Director2 2 2025-04-30 15654391 uk-bus:Director2 2 2026-04-30

# BULGARIA INTERNATIONAL MEDICAL STUDENTS ALLIANCE CIC

## Company limited by guarantee

## Company Registration Number:
15654391 (England and Wales)

## Unaudited statutory accounts for the year ended 30 April 2026

## Period of accounts

## Start date: 1 May 2025

## End date: 30 April 2026

# BULGARIA INTERNATIONAL MEDICAL STUDENTS ALLIANCE CIC

## Contents of the Financial Statements

for the Period Ended 30 April 2026

Directors report |
Profit and loss |
Balance sheet |
Additional notes |
Balance sheet notes |
Community Interest Report |

# BULGARIA INTERNATIONAL MEDICAL STUDENTS ALLIANCE CIC

Directors' report period ended 30 April 2026

The directors present their report with the financial statements of the company for the period ended 30 April 2026

Principal activities of the company

The principal activities of the company during the financial year were to provide educational, professional development and community support activities for medical students and graduates of Bulgarian medical universities, particularly those seeking to progress their careers in the United Kingdom. BIMSA continued to deliver educational content both online and in person, including teaching sessions, careers guidance and interview preparation courses for graduates applying for UK medical posts. The company also supported peer networking, knowledge-sharing and practical guidance for internationally trained medical graduates navigating the transition from medical education in Bulgaria to clinical practice and postgraduate training in the UK. These activities were undertaken to improve access to relevant educational support, promote professional development and strengthen links between medical students, graduates and doctors with experience of UK medical practice.

Directors

The director shown below has held office during the whole of the period from
1 May 2025 to 30 April 2026

James Moore

The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
3 May 2026

And signed on behalf of the board by:
Name: James Moore
Status: Director

# BULGARIA INTERNATIONAL MEDICAL STUDENTS ALLIANCE CIC

## Profit And Loss Account

for the Period Ended 30 April 2026

| 2026 | 2025
--- | --- | ---
| £ | £
Turnover: | 489 | 509
Cost of sales: | 0 | 0
Gross profit(or loss): | 489 | 509
Administrative expenses: | ( 474 ) | ( 492 )
Operating profit(or loss): | 15 | 17
Profit(or loss) before tax: | 15 | 17
Profit(or loss) for the financial year: | 15 | 17

# BULGARIA INTERNATIONAL MEDICAL STUDENTS ALLIANCE CIC

## Balance sheet

As at 30 April 2026

| Notes | 2026 | 2025
--- | --- | --- | ---
|  | £ | £
Creditors: amounts falling due within one year: | 3 | ( 219 ) | 0
Net current assets (liabilities): |  | (219) | 0
Total assets less current liabilities: |  | (219) | 0
Total net assets (liabilities): |  | (219) | 0
Members' funds
Profit and loss account: |  | (219) | 0
Total members' funds: |  | ( 219) | 0

The notes form part of these financial statements

# BULGARIA INTERNATIONAL MEDICAL STUDENTS ALLIANCE CIC

## Balance sheet statements

For the year ending 30 April 2026 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 3 May 2026
and signed on behalf of the board by:

Name: James Moore
Status: Director

The notes form part of these financial statements

# BULGARIA INTERNATIONAL MEDICAL STUDENTS ALLIANCE CIC

## Notes to the Financial Statements

for the Period Ended 30 April 2026

- ## 1. Accounting policies

  Basis of measurement and preparation

  These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

  Turnover policy

  Turnover represents income received and receivable from the provision of educational courses, events and related activities during the financial year, excluding VAT where applicable

# BULGARIA INTERNATIONAL MEDICAL STUDENTS ALLIANCE CIC

## Notes to the Financial Statements

for the Period Ended 30 April 2026

- ## 2. Employees

  | 2026 | 2025
  --- | --- | ---
  Average number of employees during the period | 0 | 0

# BULGARIA INTERNATIONAL MEDICAL STUDENTS ALLIANCE CIC

## Notes to the Financial Statements

for the Period Ended 30 April 2026

## 3. Creditors: amounts falling due within one year note

| 2026 | 2025
--- | --- | ---
| £ | £
Taxation and social security |  | 0
Other creditors | 219 |
Total | 219 | 0

# BULGARIA INTERNATIONAL MEDICAL STUDENTS ALLIANCE CIC

## Notes to the Financial Statements

for the Period Ended 30 April 2026

## 4. Loans to directors

Name of director receiving advance or credit: |
Description of the transaction:
Advance for Canva subscription, filing and tax
| £
--- | ---
Balance at 30 April 2025 | 119
Advances or credits made: |
Advances or credits repaid: |
Balance at 30 April 2026 | 119
Name of director receiving advance or credit: |
Description of the transaction:
Google subscription advance
| £
Balance at 30 April 2025 | 100
Advances or credits made: |
Advances or credits repaid: |
Balance at 30 April 2026 | 100

# COMMUNITY INTEREST ANNUAL REPORT

### BULGARIA INTERNATIONAL MEDICAL STUDENTS ALLIANCE CIC

### Company Number: 15654391 (England and Wales)

### Year Ending: 30 April 2026

Company activities and impact

BIMSA’s activities have benefited the community during the financial year by continuing to provide accessible educational, professional development, and peer-support opportunities for medical students and graduates of Bulgarian medical universities, particularly those seeking to progress their careers in the United Kingdom. The company has delivered educational content both in person and online, helping to make support available to a wider community regardless of location. This has included teaching sessions, careers guidance, and practical preparation for key transition points in medical training and employment. A significant area of benefit has been the provision of interview preparation courses for graduates of Bulgarian medical universities applying to work in the UK. These sessions support international medical graduates by helping them understand the expectations of UK medical recruitment, improve their interview technique, and prepare more confidently for clinical and professional scenarios. This contributes to better informed and better prepared doctors entering the UK workforce. The company’s work has also helped create a supportive professional network for students and graduates who may otherwise have limited access to tailored guidance. By sharing knowledge, experience, and practical advice, BIMSA has supported members of the community in navigating the challenges of transitioning from medical education in Bulgaria to clinical practice and postgraduate training in the UK. Overall, BIMSA has provided community benefit by improving access to education, supporting career progression, promoting professional development, and reducing barriers for internationally trained doctors and medical graduates seeking to work in the NHS.

Consultation with stakeholders

BIMSA has consulted with stakeholders throughout the financial year through ongoing engagement with its community of medical students, graduates of Bulgarian medical universities, UK based doctors, educators, and volunteers involved in delivering teaching and support. Consultation has taken place informally through direct communication with students and graduates attending BIMSA events, online teaching sessions, and interview preparation courses. Feedback from participants has helped identify the areas where support is most needed, including guidance on applying for UK clinical posts, preparing for interviews, understanding NHS expectations, and navigating the transition from medical school in Bulgaria to working in the UK. BIMSA has also engaged with graduates and doctors who have successfully progressed into UK medical practice. Their input has been used to shape the content of educational sessions and ensure that the advice provided is practical, relevant, and grounded in current experience. This has helped ensure that teaching and careers support reflect the real challenges faced by graduates entering the UK healthcare system. In addition, BIMSA has maintained communication with volunteers, speakers, and organisers involved in delivering educational content. Their feedback has informed the planning, format, and delivery of activities, including whether sessions should be delivered online, in person, or as a combination of both to maximise accessibility. Overall, stakeholder consultation has helped BIMSA ensure that its activities remain responsive to the needs of its community, particularly medical students and graduates seeking support with career progression, interview preparation, and integration into UK medical practice.

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
3 May 2026

And signed on behalf of the board by:
Name: James Moore
Status: Director